Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03571321
Other study ID # IRB17-1110
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 28, 2019
Est. completion date September 5, 2027

Study information

Verified date November 2023
Source University of Chicago
Contact Clinical Trials Office
Phone 1-855-702-8222
Email cancerclinicaltrials@bsd.uchicago.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test if adding ruxolitinib to standard multi-drug chemotherapy regimen will be safe and tolerated in adolescents and young adults with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL).


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date September 5, 2027
Est. primary completion date September 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria: - Newly diagnosed de novo B-precursor acute lymphoblastic leukemia (ALL) as determined by World Health Organization (WHO) criteria. Patients must have unequivocal diagnosis of precursor B ALL. This includes an institutional immunophenotyping report that is to assign B-lineage or T-lineage. - "Ph-like" signature, as determined by low density micro-array (LDA) card - Jak-targetable genetic signature as defined by any of the following: - Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type) - JAK2 or erythropoietin receptor (EPOR) fusions. - Other JAK pathway alterations at the discretion of the principle investigator including, but not limited to: - SH2B adaptor protein 3 (SH2B3) deletions - Interleukin-7 receptor subunit alpha (IL7RA) mutations - Prior therapy - Prior to starting ruxolitinib, patients must have completed a 4-drug induction regimen with intrathecal chemotherapy (modified aBFM regimen or equivalent) as per the institutional standard of care. Recommended induction treatment is outlined in Section 5.1.2. - No additional prior therapy for acute leukemia except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava syndrome, or renal failure due to leukemic infiltration of the kidneys. When indicated, leukapheresis or exchange transfusion is recommended to reduce the white blood cell count (WBC). - Screening may occur at any point prior to or during induction therapy - Age = 18 years and < 40 years. Because this is specifically a study of the adolescent and young adult population and no adverse event data are currently available on the use of this pediatric-based chemotherapy regimen in patients = 40 years of age, older adults are excluded from this study, but may be eligible for future trials. - Eastern Cooperative Oncology Group (ECOG) performance status =2 (Karnofsky = 60%) - Platelet count > 25,000/uL. - Patients must have normal organ function as defined below: - total bilirubin = 2 mg/dL - aspartate aminotransferase (AST) / alanine aminotransferase (ALT) = 2.5 × institutional upper limit of normal - creatinine within normal institutional limits OR creatinine clearance = 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. - Because the therapeutic agents used in this study are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Patients who are receiving any other investigational agent. - Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for = 3 years. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to ruxolitinib or other agents used in study. - Use of any potent cytochrome P450 (CYP) 3A4 inhibitor or inducer within 5 half-lives before the first dose of the study drug. Potent inhibitors of CYP3A4 include systemic ketoconazole, posaconazole, voriconazole, clarithromycin, itraconazole, nefazodone, and telithromycin. At the fluconazole dose of 200mg daily used this regimen, there is minimal inhibition of CYP3A4 [36] and therefore fluconazole is not prohibited on this trial and no dose modifications should be made in the presence of fluconazole. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Pregnant women are excluded from this study because ruxolitinib is a class C agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib breastfeeding should be discontinued if the mother is treated with ruxolitinib. These potential risks may also apply to other agents used in this study. - Down Syndrome due to the likelihood of excessive toxicity resulting. These patients should be treated in consultation with a pediatric oncologist. - Burkitt type leukemia - Ph+ ALL at time of diagnosis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ruxolitinib
Participants will receive one of 3 doses [taken by mouth] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study. Remission consolidation regimen: Days 1-14 and 29-43 Interim maintenance regimen: Days 1-14 and 29-43 Delayed Intensification regimen: Days 1-14 and 29-43
Cyclophosphamide
Remission consolidation regimen: 1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29 Delayed Intensification regimen: 1000 mg/m2 IV on Day 29
Cytarabine
Remission consolidation regimen: 75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39 Delayed Intensification regimen: 75 mg/m2/day IV or SC on Days 29-32 and 36-39
Mercaptopurine
Taken by mouth. Remission consolidation regimen: 60 mg/m2 on Days 1-14 and 29-42 Maintenance Therapy: 75 mg/m2 on Days 1-84
Vincristine
Remission consolidation regimen: 1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50 Interim maintenance regimen: 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41 Delayed Intensification regimen: 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50 Maintenance Therapy: 1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57
Pegaspargase
Remission consolidation regimen: 2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43 Interim maintenance regimen: 2500 IU/m2 IM or IV on Days 2 and 22 Delayed Intensification regimen: 2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43.
Rituximab
For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only. Remission consolidation regimen: 375 mg/m2 IV on Days 1, 8, 29 and 36 Interim maintenance regimen: 375 mg/m2 IV on Days 1 and 11 Delayed Intensification regimen: 375 mg/m2 IV on Days 1 and 8
Methotrexate (Intrathecal Administration)
Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal [IT] administration). Remission consolidation regimen: 15 mg on Days 1, 8, 15, and 22 Interim maintenance regimen: 15 mg on Days 1 and 31 Delayed Intensification regimen: 15 mg on Days 1, 29, and 36 Maintenance Therapy: 15 mg on Day 1 15 mg on Day 29 (First 4 courses only)
Methotrexate (Intravenous Administration)
Interim maintenance regimen: 100 mg/m2 IV on Days 1, 11, 21, 31, and 41
Dexamethasone
Taken by mouth or given by IV infusion. Delayed Intensification regimen: 10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21 Maintenance Therapy: 6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61
Doxorubicin
Delayed Intensification regimen: 25 mg/m2 IV on Days 1, 8, 15
Thioguanine
Taken by mouth at least 1 hour after evening meal. Delayed Intensification regimen: 60 mg/m2 on Days 29-42
Methotrexate Oral Product
Taken by mouth. Maintenance Therapy: 20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78) Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given]

Locations

Country Name City State
United States University of Chicago Medical Center Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
University of Chicago Incyte Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of adding ruxolitinib to a standard-of-care pediatric-based chemotherapy regimen in adolescents and young adult patients as determined by rate of side effects seen when combination is given Determined by rate of side effects seen when combination is given 24 weeks
Secondary Rate of participants that are minimal residual disease (MRD) negative at end of induction therapy 4 weeks
Secondary Overall survival rate 2 years
Secondary Event-free survival rate 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT05772000 - Clinical Significance of Occult Central Nervous System Localization
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT03114865 - A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Phase 1/Phase 2
Not yet recruiting NCT06308588 - Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Phase 2
Recruiting NCT05579132 - A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT02231853 - Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT06195891 - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Phase 1
Withdrawn NCT02815059 - Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone Phase 1
Completed NCT00390793 - Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Phase 2
Recruiting NCT05866887 - Insomnia Prevention in Children With Acute Lymphoblastic Leukemia N/A
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06350994 - Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Not yet recruiting NCT04488237 - Vitamin D and Methotrexate Adverse Effects
Completed NCT02544438 - Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Phase 1/Phase 2